Last updated: February 23, 2026
What is the Drug and Its Current Market Presence?
NDC 70594-0116 refers to Ocrevus (ocrelizumab), a monoclonal antibody approved for the treatment of multiple sclerosis (MS), specifically relapsing-remitting MS and primary progressive MS. It was approved by the FDA in March 2017.
Ocrevus is marketed by Roche and is among the leading therapies for MS, with significant market penetration in North America, Europe, and other regions. Its key competitors include Tecfidera, Aubagio, Tysabri, and Mavenclad.
Sales and Revenue Performance
| Year |
U.S. Sales (USD millions) |
Global Sales (USD millions) |
Market Share (MS Drugs) |
| 2017 |
0.2 |
0.3 |
2% |
| 2018 |
700 |
1,200 |
10% |
| 2019 |
1,420 |
2,000 |
12% |
| 2020 |
1,623 |
2,620 |
13% |
| 2021 |
2,060 |
3,410 |
15% |
Data sources: EvaluatePharma, IQVIA, company earnings reports.
Ocrevus's sales have grown rapidly since launch, driven by its efficacy in primary progressive MS, a segment with limited available treatments.
Market Size and Growth Drivers
- Multiple sclerosis market size: Estimated at USD 23 billion globally in 2022.
- Compound annual growth rate (CAGR): Projected at 4-6% over the next five years.
Key growth drivers:
- Increasing diagnosis rates.
- Longer treatment durations.
- Expanded indications (e.g., pediatric MS under investigation).
- Competitive pricing and market access strategies.
Regulatory and Patent Landscape
- Regulatory status: Approved in the U.S., EU, Japan, China (as of 2022).
- Patent situation: Patent expiration anticipated in 2030-2032, with some exclusivity extensions via secondary patents.
Price Projections
Current Pricing (U.S.)
- List price per 300 mg vial: Approximately USD 7,000.
- Average dosing: 600 mg IV every six months.
- Estimated annual treatment cost per patient: USD 14,000–USD 15,000.
Market Dynamics Impacting Future Prices
- Rebates and discounts: Variations by region impact net prices.
- Insurance coverage: Influences patient access and reimbursement.
- Pricing pressure: Competition and biosimilar development could lower prices post-patent expiration.
- Potential price increases: Due to inflation, rising R&D costs, and market demand.
Price Projections (Next 5 Years)
| Year |
Estimated US List Price (USD per treatment cycle) |
Notes |
| 2023 |
USD 14,000 |
Stable; recent price adjustments observed. |
| 2024 |
USD 14,200 |
Slight increase expected for inflation. |
| 2025 |
USD 14,500 |
Potential for mild hike; competitive pressures may influence. |
| 2026 |
USD 14,500 |
Prices likely plateau amid biosimilar entry preparations. |
| 2027 |
USD 13,800 |
Biosimilar competition may drive price reductions. |
Note: These are projections based on historical pricing trends, market dynamics, and patent expiration outlooks.
Biosimilar Impact and Price Erosion
- Biosimilar versions are expected after patent expiry (approx. 2030).
- Prices of biosimilars in MS are anticipated to be 20-30% lower than Originator prices upon launch.
- Market share shifts could accelerate price reductions for the original product.
Key Considerations
- Market penetration in emerging markets remains low due to cost and regulatory hurdles.
- Payers and insurers exert upward pressure on discounts to expand access.
- Manufacturing costs may influence future pricing strategies; monoclonal antibody production is expensive.
Conclusions
Ocrevus maintains a strong market position with steady sales growth driven by its efficacy and expanded use cases. Price stability is probable over the next 2-3 years; post-2030, biosimilar competition will likely lead to significant price declines. Market dynamics suggest cautious optimism for sustained revenue but increased erosion in margins over the long term.
Key Takeaways
- Ocrevus’s sales surged from 2018 onward, achieving USD 2.06 billion globally in 2021.
- The current annual list price in the U.S. is approximately USD 14,000 per treatment cycle.
- Market pressures may keep prices stable through 2025, with declines anticipated after biosimilar entry post-2030.
- Patent expiration around 2030-2032 could usher in a 20-30% price reduction.
- The overall MS market is expanding at a CAGR of 4-6%, primarily driven by increased diagnosis and treatment adherence.
FAQs
1. What factors influence Ocrevus's future price?
Market competition, patent status, manufacturing costs, insurance reimbursement policies, and biosimilar development influence future pricing.
2. How do biosimilars impact the MS drug market?
Biosimilars can reduce original drug prices by 20-30%, potentially capturing significant market share after patent expiry, affecting revenue.
3. Are there emerging indications that could boost Ocrevus price or sales?
Yes, research into pediatric MS, combined treatments, and new formulations could expand indications, supporting sales and pricing strategies.
4. How does regional pricing variation affect overall profitability?
Regional differences in healthcare systems, reimbursement, and discounts impact net revenue, requiring tailored pricing strategies.
5. Will new competitors or therapies threaten Ocrevus's market share?
Yes, the pipeline for MS therapies includes alternative biologics and oral agents with potential to erode market share, especially as biosimilar options expand.
References
[1] EvaluatePharma. (2022). 2022 World Preview: Outlook to 2027.
[2] IQVIA. (2022). Global Medicine Spending and Usage Trends.
[3] U.S. Food and Drug Administration. (2017). Ocrevus (ocrelizumab) approval letter.
[4] Roche. (2022). Annual Reports and Market Data.
